Conatus Data First Step In Liver Drug Pivotal Trial Design
This article was originally published in Scrip
Executive Summary
Conatus Pharmaceuticals Inc. reported mostly positive data from the first of two Phase II clinical trials that are meant to inform the design of pivotal trials for emricasan in the treatment of liver cirrhosis associated with alcoholism, non-alcoholic steatohepatitis (NASH) and the hepatitis C virus (HCV).